Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects

<b>Background and Objectives:</b> Alendronate, an aminobisphosphonate, is capable of inhibiting periodontitis associated osteoclastic activity and hence is effective in protecting the alveolar bone in periodontitis. In the present study, we explored the efficacy of local delivery of ale...

Full description

Bibliographic Details
Main Authors: Veena H, Prasad Deepak
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2010-01-01
Series:Journal of Indian Society of Periodontology
Subjects:
Online Access:http://www.jisponline.com/article.asp?issn=0972-124X;year=2010;volume=14;issue=1;spage=40;epage=45;aulast=Veena
_version_ 1818877725491855360
author Veena H
Prasad Deepak
author_facet Veena H
Prasad Deepak
author_sort Veena H
collection DOAJ
description <b>Background and Objectives:</b> Alendronate, an aminobisphosphonate, is capable of inhibiting periodontitis associated osteoclastic activity and hence is effective in protecting the alveolar bone in periodontitis. In the present study, we explored the efficacy of local delivery of alendronate on the alveolar bone following mucoperiosteal flap surgery. This is the first study to use polymer impregnated gel based delivery of alendronate. <b> Materials and Methods:</b> A total of 15 patients with chronic periodontitis in the age group of 35 - 55 years, of both sexes, with pocket depth of &#8805; 5mm and radiographic evidence of identical osseous defects in the mandibular molar region bilaterally were included in this prospective study. A gel based drug delivery system of Alendronate was formulated. Following surgical flap debridement, 0.1 ml alendronate gel and 0.1 ml placebo gel was placed at the experimental and control sites respectively. Clinical and radiographic parameters were recorded at baseline, three months and six months post surgery. <b> Results:</b> Alendronate was more effective in improving clinical and radiographic parameters compared to placebo. <b> Interpretation and Conclusion:</b> Alendronate is effective in the management of periodontitis associated bone loss. Gel based local delivery of the drug addresses the critical concern of exposing the patient to adverse effects of systemic administration.
first_indexed 2024-12-19T14:02:51Z
format Article
id doaj.art-8b0f3dbfc3b54de7a4a143d8837b5715
institution Directory Open Access Journal
issn 0972-124X
0975-1580
language English
last_indexed 2024-12-19T14:02:51Z
publishDate 2010-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Indian Society of Periodontology
spelling doaj.art-8b0f3dbfc3b54de7a4a143d8837b57152022-12-21T20:18:25ZengWolters Kluwer Medknow PublicationsJournal of Indian Society of Periodontology0972-124X0975-15802010-01-011414045Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defectsVeena HPrasad Deepak<b>Background and Objectives:</b> Alendronate, an aminobisphosphonate, is capable of inhibiting periodontitis associated osteoclastic activity and hence is effective in protecting the alveolar bone in periodontitis. In the present study, we explored the efficacy of local delivery of alendronate on the alveolar bone following mucoperiosteal flap surgery. This is the first study to use polymer impregnated gel based delivery of alendronate. <b> Materials and Methods:</b> A total of 15 patients with chronic periodontitis in the age group of 35 - 55 years, of both sexes, with pocket depth of &#8805; 5mm and radiographic evidence of identical osseous defects in the mandibular molar region bilaterally were included in this prospective study. A gel based drug delivery system of Alendronate was formulated. Following surgical flap debridement, 0.1 ml alendronate gel and 0.1 ml placebo gel was placed at the experimental and control sites respectively. Clinical and radiographic parameters were recorded at baseline, three months and six months post surgery. <b> Results:</b> Alendronate was more effective in improving clinical and radiographic parameters compared to placebo. <b> Interpretation and Conclusion:</b> Alendronate is effective in the management of periodontitis associated bone loss. Gel based local delivery of the drug addresses the critical concern of exposing the patient to adverse effects of systemic administration.http://www.jisponline.com/article.asp?issn=0972-124X;year=2010;volume=14;issue=1;spage=40;epage=45;aulast=VeenaAlendronate/therapeutic usealveolar bone lossbisphosphonates/therapeutic usebone resorptionosteoclastssurgical flaps
spellingShingle Veena H
Prasad Deepak
Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects
Journal of Indian Society of Periodontology
Alendronate/therapeutic use
alveolar bone loss
bisphosphonates/therapeutic use
bone resorption
osteoclasts
surgical flaps
title Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects
title_full Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects
title_fullStr Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects
title_full_unstemmed Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects
title_short Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects
title_sort evaluation of an aminobisphosphonate alendronate in the management of periodontal osseous defects
topic Alendronate/therapeutic use
alveolar bone loss
bisphosphonates/therapeutic use
bone resorption
osteoclasts
surgical flaps
url http://www.jisponline.com/article.asp?issn=0972-124X;year=2010;volume=14;issue=1;spage=40;epage=45;aulast=Veena
work_keys_str_mv AT veenah evaluationofanaminobisphosphonatealendronateinthemanagementofperiodontalosseousdefects
AT prasaddeepak evaluationofanaminobisphosphonatealendronateinthemanagementofperiodontalosseousdefects